Fortis Capital Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Fortis Capital Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-40,000	Closed	-$2.07M	–	134
2021 Q2	$2.07M	Buy	+40,000	New	+$2.01M	1.05%	46

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Fortis Capital Management's XPH Position: Q3 2021 in Review

Fortis Capital Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2021, closing a stake of 40,000 shares — an estimated $2.07M sold.

Fortis Capital Management first reported a position in XPH in Q2 2021 and held it in 1 quarter. The position peaked at $2.07M in Q2 2021. 78 funds tracked by Wall St. Rank hold XPH as of Q3 2021.

Fortis Capital Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2021 after selling out during the quarter.
Fortis Capital Management sold 40,000 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2021, an estimated $2.07M.
Fortis Capital Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2021 and held it in 1 quarter.
Fortis Capital Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2.07M in Q2 2021.
78 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2021.

Based on Fortis Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.